Genelux Corporation is a privately-held, clinical stage biopharmaceutical company that has developed a proprietary oncolytic virus based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy.
the company’s lead oncology product candidate is an attenuated vaccina virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1
encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1
currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1
is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.
The company’s R&D efforts and leadership in the field of Oncolytic Virotherapy have yielded a wide variety of new applications for its platform and imaging technologies, including:
Genelux is headquartered in California, with additional operations in Germany.